Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00749658 · ClinicalTrials.gov registry record · Phase 2
Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT00749658 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 121 participants.
The verdict
NCT00749658, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
The objective of this proposal is to elucidate effects of bupropion SR + varenicline on smoking-cessation related processes in early abstinence using a human laboratory model. A within-subjects design will be used to assess the additive effects of bupropion and varenicline in 48 treatment seeking smokers \[bupropion SR (300 mg/day)+placebo, varenicline (2 mg/day+placebo, and bupropion SR (300 mg/day)+varenicline (2 mg/day)\]. Outcomes include withdrawal and craving, cognition, stress tolerance, anxiety, the reinforcing effects of smoking, and smoking topography. Hypotheses: We hypothesize that greatest treatment effects will be observed in the bupropion SR+varenicline group followed by varenicline+placebo and bupropion SR+placebo groups.
Interventions
- DRUG Varenicline
- DRUG Bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00749658
The ClinicalTrials.gov registry entry for NCT00749658 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Varenicline is the first listed.
NCT00749658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00749658 about?
NCT00749658 is a clinical study titled "Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence". The objective of this proposal is to elucidate effects of bupropion SR + varenicline on smoking-cessation related processes in early abstinence using a human laboratory model. A within-subjects design will be used to assess the additive effects of bupropion and varenicline in 48 treatment seeking sm...
What is the current status of trial NCT00749658?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2008-11. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00749658?
The interventions under investigation include: Varenicline (DRUG), Bupropion (DRUG).
Who is sponsoring clinical trial NCT00749658?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.